Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTOG-1112: Sorafenib vs SBRT + Sorafenib in HCC
NCT01730937Phase 3Completed
- Sponsor
- NRG Oncology
- Start
- Apr 2013
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by NRG Oncology. Started Apr 2013; status: completed.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01730937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01730937.